Key facts
- It has raised $20K; the latest was Later Stage VC in Jul 2025.
- Notable investors include Creative Destruction Lab, MassChallenge, Impact Assets, Harvard Innovation Launch Lab, Catalytic Impact Foundation — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Limax Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Limax Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Limax Biosciences
Developer of a degradable adhesive hydrogel designed for hemostasis, wound closure, and drug delivery. The company's adhesive is stretchy and flexible, based on bio-inspired materials, to seal wounds and promote healing throughout the body, enabling healthcare professionals to utilize it in multiple indication areas.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Employees
- 10
- Website
- limaxbiosciences.com/
- Ownership
- Privately Held (backing)
Limax Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Limax Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Limax Biosciences in its N-PORT filings yet. We sweep new filings monthly.